0001551986FALSE00015519862022-10-212022-10-21

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
 
FORM 8-K
 
 
 
CURRENT REPORT
Pursuant to Section 13 of 15(d)
of the Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): October 21, 2022
 
 
 
9 Meters Biopharma, Inc.
(Exact name of registrant as specified in its charter)
 
 
 
Delaware 001-37797 27-3948465
(State or other jurisdiction of
incorporation or organization)		 (Commission
File Number)		 (I.R.S. Employer
Identification No.)
 
8480 Honeycutt Road, Suite 120, Raleigh, NC 27615
(Address of principal executive offices) (Zip Code)
 
(919) 275-1933
(Registrant’s telephone number, include area code)
 
N/A
(Former Name or Former Address, if Changed Since Last Report)
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock $0.0001 Par ValueNMTRThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 


Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07.Submission of Matters to a Vote of Security Holders.
On October 21, 2022, 9 Meters Biopharma, Inc. (the “Company”) reconvened the Company’s special meeting of stockholders (the “Special Meeting”), which was previously adjourned on September 23, 2022. At the close of business on July 25, 2022, the record date of the Special Meeting, the Company had 259,107,380 shares of common stock issued and outstanding. The holders of a total of 131,584,292 shares of common stock eligible to vote on the record date were present at the Special Meeting, either in person or by proxy, which constituted a quorum for the Special Meeting. At the Special Meeting, stockholders voted on the proposal to approve the potential issuance of shares the Company’s common stock underlying secured convertible notes in an amount that may be equal to or exceed 20% of the Company’s common stock outstanding, in order to comply with Nasdaq Listing Rule 5635(d). The final voting results for such proposal are set forth below:


Votes For
Votes Against		Votes AbstainedBroker Non-Votes
116,809,60013,548,7751,225,917--







  
 



SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
    
 9 Meters Biopharma, Inc.
    
Date: October 21, 2022By: /s/ Bethany Sensenig
   Bethany Sensenig
   Chief Financial Officer